<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Pathog</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Pathog</journal-id><journal-id journal-id-type="pmc-domain-id">349</journal-id><journal-id journal-id-type="pmc-domain">plospath</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLoS Pathogens</journal-title></journal-title-group><issn pub-type="ppub">1553-7366</issn><issn pub-type="epub">1553-7374</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8757994</article-id><article-id pub-id-type="pmcid-ver">PMC8757994.1</article-id><article-id pub-id-type="pmcaid">8757994</article-id><article-id pub-id-type="pmcaiid">8757994</article-id><article-id pub-id-type="pmid">35025969</article-id><article-id pub-id-type="doi">10.1371/journal.ppat.1010161</article-id><article-id pub-id-type="publisher-id">PPATHOGENS-D-21-02000</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Coronaviruses</subject><subj-group><subject>SARS coronavirus</subject><subj-group><subject>SARS CoV 2</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Model Organisms</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Experimental Organism Systems</subject><subj-group><subject>Animal Models</subject><subj-group><subject>Mouse Models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Animal Studies</subject><subj-group><subject>Animal Models of Disease</subject><subj-group><subject>Animal Models of Infection</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Animal Models of Infection</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Eukaryota</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Rodents</subject><subj-group><subject>Hamsters</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Zoology</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Rodents</subject><subj-group><subject>Hamsters</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Covid 19</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject><subj-group><subject>Viral Vaccines</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Vaccines</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Advances and gaps in SARS-CoV-2 infection models</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7725-2586</contrib-id><name name-style="western"><surname>Mu&#241;oz-Fontela</surname><given-names initials="C">C&#233;sar</given-names></name><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6666-7770</contrib-id><name name-style="western"><surname>Widerspick</surname><given-names initials="L">Lina</given-names></name><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4008-503X</contrib-id><name name-style="western"><surname>Albrecht</surname><given-names initials="RA">Randy A.</given-names></name><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beer</surname><given-names initials="M">Martin</given-names></name><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carroll</surname><given-names initials="MW">Miles W.</given-names></name><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9763-7758</contrib-id><name name-style="western"><surname>de Wit</surname><given-names initials="E">Emmie</given-names></name><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8791-3165</contrib-id><name name-style="western"><surname>Diamond</surname><given-names initials="MS">Michael S.</given-names></name><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3277-6199</contrib-id><name name-style="western"><surname>Dowling</surname><given-names initials="WE">William E.</given-names></name><xref rid="aff009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Funnell</surname><given-names initials="SGP">Simon G. P.</given-names></name><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6551-1827</contrib-id><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names initials="A">Adolfo</given-names></name><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gerhards</surname><given-names initials="NM">Nora M.</given-names></name><xref rid="aff010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2052-5993</contrib-id><name name-style="western"><surname>de Jong</surname><given-names initials="R">Rineke</given-names></name><xref rid="aff010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2288-3196</contrib-id><name name-style="western"><surname>Munster</surname><given-names initials="VJ">Vincent J.</given-names></name><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0033-7514</contrib-id><name name-style="western"><surname>Neyts</surname><given-names initials="J">Johan</given-names></name><xref rid="aff011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perlman</surname><given-names initials="S">Stanley</given-names></name><xref rid="aff012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0076-9023</contrib-id><name name-style="western"><surname>Reed</surname><given-names initials="DS">Douglas S.</given-names></name><xref rid="aff013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7308-5672</contrib-id><name name-style="western"><surname>Richt</surname><given-names initials="JA">Juergen A.</given-names></name><xref rid="aff014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Riveros-Balta</surname><given-names initials="X">Ximena</given-names></name><xref rid="aff015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1710-6974</contrib-id><name name-style="western"><surname>Roy</surname><given-names initials="CJ">Chad J.</given-names></name><xref rid="aff016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5315-3882</contrib-id><name name-style="western"><surname>Salguero</surname><given-names initials="FJ">Francisco J.</given-names></name><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3156-3132</contrib-id><name name-style="western"><surname>Schotsaert</surname><given-names initials="M">Michael</given-names></name><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2264-3029</contrib-id><name name-style="western"><surname>Schwartz</surname><given-names initials="LM">Lauren M.</given-names></name><xref rid="aff015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seder</surname><given-names initials="RA">Robert A.</given-names></name><xref rid="aff017" ref-type="aff">
<sup>17</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1539-7261</contrib-id><name name-style="western"><surname>Segal&#233;s</surname><given-names initials="J">Joaquim</given-names></name><xref rid="aff018" ref-type="aff">
<sup>18</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7326-3210</contrib-id><name name-style="western"><surname>Vasan</surname><given-names initials="SS">Seshadri S.</given-names></name><xref rid="aff019" ref-type="aff">
<sup>19</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Henao-Restrepo</surname><given-names initials="AM">Ana Mar&#237;a</given-names></name><xref rid="aff015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5127-4659</contrib-id><name name-style="western"><surname>Barouch</surname><given-names initials="DH">Dan H.</given-names></name><xref rid="aff020" ref-type="aff">
<sup>20</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>German Center for Infection Research (DZIF), Partner Site Hamburg-L&#252;beck-Borstel-Riems, Hamburg, Germany</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Friedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald-Insel Riems, Germany</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>National Infection Service, Public Health England, Salisbury, United Kingdom</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Pandemic Sciences Centre, Nuffield Department of Medicine, Oxford University, United Kingdom</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Coalition for Epidemic Preparedness Innovations (CEPI), Washington, Washington, DC, United States of America</addr-line></aff><aff id="aff010"><label>10</label>
<addr-line>Wageningen Bioveterinary Research, Lelystad, the Netherlands</addr-line></aff><aff id="aff011"><label>11</label>
<addr-line>KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium</addr-line></aff><aff id="aff012"><label>12</label>
<addr-line>Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America</addr-line></aff><aff id="aff013"><label>13</label>
<addr-line>Center for Vaccine Research and Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line></aff><aff id="aff014"><label>14</label>
<addr-line>Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, United States of America</addr-line></aff><aff id="aff015"><label>15</label>
<addr-line>World Health Organization, Geneva, Switzerland</addr-line></aff><aff id="aff016"><label>16</label>
<addr-line>Tulane National Primate Research Center, Covington, Louisiana, United States of America</addr-line></aff><aff id="aff017"><label>17</label>
<addr-line>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line></aff><aff id="aff018"><label>18</label>
<addr-line>Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus UAB, and Departament de Sanitat i Anatomia animals, Facultat de Veterin&#224;ria, UAB, Barcelona, Spain</addr-line></aff><aff id="aff019"><label>19</label>
<addr-line>Australian Centre for Disease Preparedness, CSIRO, Geelong, Australia</addr-line></aff><aff id="aff020"><label>20</label>
<addr-line>Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Lazear</surname><given-names initials="HM">Helen M.</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of North Carolina at Chapel Hill School of Medicine, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>dbarouch@bidmc.harvard.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>1</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2022</year></pub-date><volume>18</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">397443</issue-id><elocation-id>e1010161</elocation-id><pub-history><event event-type="pmc-release"><date><day>13</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-27 13:25:26.120"><day>27</day><month>09</month><year>2024</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="cc0license">https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ppat.1010161.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="ppat.1010161.pdf"/><abstract><p>The global response to Coronavirus Disease 2019 (COVID-19) is now facing new challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern (VOCs). Preclinical models of disease, in particular animal models, are essential to investigate VOC pathogenesis, vaccine correlates of protection and postexposure therapies. Here, we provide an update from the World Health Organization (WHO) COVID-19 modeling expert group (WHO-COM) assembled by WHO, regarding advances in preclinical models. In particular, we discuss how animal model research is playing a key role to evaluate VOC virulence, transmission and immune escape, and how animal models are being refined to recapitulate COVID-19 demographic variables such as comorbidities and age.</p></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="15"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC0</meta-value></custom-meta><custom-meta id="outbreaks"><meta-name>Outbreaks</meta-name><meta-value>COVID-19</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>In February of 2020, the World Health Organization (WHO) R&amp;D Blueprint convened a group of experts to develop preclinical models of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Since its inception, the goal of this WHO COVID Modeling group (WHO-COM) has been to accelerate the development of Coronavirus Disease 2019 (COVID-19) vaccines and therapeutics by rapidly sharing data among member scientists worldwide. In addition, concerns were raised at that time about the possibility of vaccine-associated enhanced respiratory disease (VAERD) or antibody-dependent enhancement (ADE) after vaccination or infection. In September of 2020, the WHO-COM published a review on COVID-19 animal models [<xref rid="ppat.1010161.ref001" ref-type="bibr">1</xref>], which reflected the state-of-the art at that time, with the vast majority of publications authored by members of the group.</p><p>Preclinical studies in nonhuman primates (NHPs) of COVID-19 vaccines that are currently being deployed [<xref rid="ppat.1010161.ref002" ref-type="bibr">2</xref>&#8211;<xref rid="ppat.1010161.ref005" ref-type="bibr">5</xref>] proved remarkably predictive of the outcome of clinical efficacy studies. In particular, NHP studies not only predicted high clinical efficacy of these vaccines but also suggested immune correlates of protection. Moreover, preclinical studies accurately predicted that protection against severe pneumonia would be easier to achieve than protection against viral replication in nasal mucosa. These observations confirm the value and importance of the use of animal models for COVID-19.</p><p>In 2021, with several vaccines rolling out worldwide and the detection of variants of concern (VOCs), the development of preclinical models of SARS-CoV-2 infection and their role in COVID-19 research has entered into a new phase. This paper provides an update from the WHO-COM regarding advances in preclinical models. In particular, we discuss how animal model research has provided insight into VOC pathogenesis and correlates of protection and has helped therapeutic development. Finally, we discuss the current status of VAERD research and the race to develop models that recapitulate COVID-19 demographic variables such as comorbidities and age.</p><sec id="sec001"><title>Animal models to study VOCs</title><p>As the current pandemic evolves, several virus variants carrying multiple mutations have emerged in different regions of the world. Some variants have been classified by WHO as variants of interest (VOIs) or VOCs, based on epidemiological evidence of enhanced transmission and possible evasion from natural and vaccine-induced immunity [<xref rid="ppat.1010161.ref006" ref-type="bibr">6</xref>]. Animal models have a key role in the evaluation of VOC transmission, immune escape, and pathogenicity.</p><sec id="sec002"><title>Vaccine cross-protection and transmission</title><p>Recent studies in mice, hamsters, and NHPs show that animals previously infected or vaccinated against lineage A SARS-CoV-2 (for example, the original Wuhan strain) [<xref rid="ppat.1010161.ref007" ref-type="bibr">7</xref>] are protected against challenge with homologous as well as heterologous virus strains including the alpha (B.1.1.7), beta (B.1.351), gamma (B.1.1.28.1), and delta (B.1.617.2) VOCs [<xref rid="ppat.1010161.ref008" ref-type="bibr">8</xref>&#8211;<xref rid="ppat.1010161.ref014" ref-type="bibr">14</xref>]. In the NHP model, however, more viral breakthroughs were observed following beta VOC challenge as compared with homologous WA1/2020 challenge [<xref rid="ppat.1010161.ref012" ref-type="bibr">12</xref>,<xref rid="ppat.1010161.ref015" ref-type="bibr">15</xref>]. In addition to protection against disease, another concern was to determine whether reinfection with VOCs resulted in SARS-CoV-2 shedding, which would raise the possibility that asymptomatic reinfected individuals might transmit VOCs. In this regard, hamsters reinfected with VOCs were indeed shown to shed SARS-CoV-2 for a number of days [<xref rid="ppat.1010161.ref008" ref-type="bibr">8</xref>,<xref rid="ppat.1010161.ref014" ref-type="bibr">14</xref>,<xref rid="ppat.1010161.ref016" ref-type="bibr">16</xref>]. However, transmission studies performed in cats indicated that infected animals did not shed enough virus for transmission to cohoused na&#239;ve sentinel cats [<xref rid="ppat.1010161.ref017" ref-type="bibr">17</xref>]. These results are in agreement with the finding that, although vaccinated individuals can be reinfected, transmission of delta VOC from these individuals may be substantially reduced in comparison with nonvaccinated subjects [<xref rid="ppat.1010161.ref018" ref-type="bibr">18</xref>]. Importantly, virus shedding in hamsters, ferrets, and NHPs was reduced by intranasal vaccination [<xref rid="ppat.1010161.ref019" ref-type="bibr">19</xref>,<xref rid="ppat.1010161.ref020" ref-type="bibr">20</xref>], showing perhaps an added value of mucosal vaccines to control VOC expansion.</p><p>It is now clear, however, that, in competition studies, at least the alpha and beta VOCs show enhanced transmission in comparison with lineage A SARS-CoV-2 in a number of models, including hamsters, ferrets, and white-tailed deer [<xref rid="ppat.1010161.ref021" ref-type="bibr">21</xref>&#8211;<xref rid="ppat.1010161.ref024" ref-type="bibr">24</xref>]. This attribute could be dependent, at least partially, on the presence of VOC-specific spike substitutions such as N501Y, D614G, and V367F, which improve the affinity of the SARS-CoV-2 spike protein for the human and hamster angiotensin-converting enzyme 2 (ACE2) receptors. The aromatic N501Y substitution that is present in the alpha, beta, and gamma VOC is associated with increased transmission in humans but also allows for infection in the wild-type mouse using the mouse ACE2 receptor [<xref rid="ppat.1010161.ref025" ref-type="bibr">25</xref>]. Thus, 2 recent studies have shown that wild-type mice are susceptible to certain SARS-CoV-2 VOCs, specifically to the beta (B.1.351) and gamma (P1) VOCs [<xref rid="ppat.1010161.ref026" ref-type="bibr">26</xref>,<xref rid="ppat.1010161.ref027" ref-type="bibr">27</xref>], most likely due to the N501Y substitution. Although mild lesions and viral replication were observed in nasal turbinates and lung of these wild-type mice inoculated with these VOCs, no significant clinical signs were observed. These results open the avenue to use wild-type mice as a potential animal model of asymptomatic infection with SARS-CoV-2, mainly to study immune responses, for which laboratory reagents are widely available. More threatening, these observations also raise concerns on the possibility of interspecies transmission, with new variants expanding their tropism toward other animal species resistant to the ancestral viral strains and, eventually, becoming novel secondary viral reservoirs [<xref rid="ppat.1010161.ref028" ref-type="bibr">28</xref>]. However, the highly relevant delta variant has a different mutation pattern that does not include an N501Y substitution, but a P to R substitution in the spike protein cleavage site and therefore may react differently in the animal models than other VOCs. This raises the possibility that SARS-CoV-2 could also evolve into a human-specific virus with reduced cross-infective properties in other mammals. In this regard, human tissue culture microfluidic systems have been developed to supplement the infection modeling landscape [<xref rid="ppat.1010161.ref029" ref-type="bibr">29</xref>,<xref rid="ppat.1010161.ref030" ref-type="bibr">30</xref>] and may offer a scalable solution to such a scenario if it were to emerge. Characterization in the full spectrum of available models and systems and with different delta VOC isolates is therefore suggested. However, it must always be kept in mind that the emergence of additional new VOCs will lead to a time delay in testing in animal models, since the selected viruses must first be isolated and characterized in vitro and subsequently distributed to the different laboratories worldwide.</p></sec><sec id="sec003"><title>VOC pathogenesis in animal models</title><p>Importantly, even though VOCs readily infected the lower respiratory tract of hamsters and NHPs, none of these variants seemed to show enhanced virulence in these animal models, although increased production of proinflammatory cytokines was observed in hamsters infected with the alpha VOC [<xref rid="ppat.1010161.ref009" ref-type="bibr">9</xref>]. In a comparative study carried out in rhesus macaques, infection with the beta VOC resulted in lower clinical scores and lower levels of virus replication in comparison with ancestral B.1 virus and alpha VOC [<xref rid="ppat.1010161.ref031" ref-type="bibr">31</xref>]. These findings were confirmed in a direct comparison between B.1 and alpha VOC infection in African green monkeys [<xref rid="ppat.1010161.ref032" ref-type="bibr">32</xref>]. Conversely, studies in other models such as transgenic mice expressing the human ACE2 (huACE2) receptor driven by the cytokeratin-18 (K18) gene promoter (K18-huACE2) have yielded different outcomes. In these mice, infection with the beta VOC resulted in enhanced infectivity and a quicker disease progression in comparison to one of ancestral variants (B.1) [<xref rid="ppat.1010161.ref026" ref-type="bibr">26</xref>]. Such enhanced infectivity could be due, at least to some extent, to the expression of higher levels of interferon antagonist proteins by some VOCs [<xref rid="ppat.1010161.ref033" ref-type="bibr">33</xref>]. Other studies have, however, shown reduced fitness of the beta VOC in mice in competition trials [<xref rid="ppat.1010161.ref022" ref-type="bibr">22</xref>] (<xref rid="ppat.1010161.g001" ref-type="fig">Fig 1</xref>). One possible explanation for differences in VOC virulence when comparing results in different animal models is the rise of mutations leading to increased processing and fusion by the S protein of SARS-CoV-2 [<xref rid="ppat.1010161.ref034" ref-type="bibr">34</xref>,<xref rid="ppat.1010161.ref035" ref-type="bibr">35</xref>]. As VOC phenotypic features appear dependent on interactions with host factors, experimental demonstration of enhanced virulence or transmission with emerging VOC may depend on the animal model and the specific VOC strain used. One strategy to minimize the variables during experiments has been the use of syngeneic viral backbones generated by reverse genetics [<xref rid="ppat.1010161.ref036" ref-type="bibr">36</xref>]. This approach demonstrated the fitness advantage of S-614G versus S-614D in a syngeneic direct competition assay [<xref rid="ppat.1010161.ref021" ref-type="bibr">21</xref>] and recently also demonstrated the role of the spike protein of the alpha VOC for enhanced transmission properties in a transgenic mouse model [<xref rid="ppat.1010161.ref022" ref-type="bibr">22</xref>]. It is important to consider that various experimental setups and the use of different VOCs could affect the experimental outcome. A series of experiments in different animal models and with different VOCs are necessary for particularly robust conclusions.</p><fig position="float" id="ppat.1010161.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1010161.g001</object-id><label>Fig 1</label><caption><title>SARS-CoV-2 VOC in animal models.</title><p>The schematic summarizes findings related with virulence, transmission, and cross-protection gathered in the indicated animal models so far. Figure created with Biorender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biorender.com/" ext-link-type="uri">Biorender.com</ext-link>). huACE2, human angiotensin I-converting enzyme 2; K18, cytokeratin-18; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; VOC, variant of concern.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1010161.g001.jpg"/></fig></sec></sec><sec id="sec004"><title>Vaccine-associated enhanced respiratory disease</title><p>Vaccine-associated enhanced disease (VAED) defines adverse events that affect individuals infected with a pathogen after receiving a prior vaccine against that same pathogen. More specifically, VAERD was observed in individuals immunized with formalin-inactivated vaccines against measles or respiratory syncytial virus (RSV) decades ago [<xref rid="ppat.1010161.ref037" ref-type="bibr">37</xref>,<xref rid="ppat.1010161.ref038" ref-type="bibr">38</xref>]. ADE, on the other hand, is a phenomenon where preexisting vaccine or infection-induced antibodies enhance infection of Fc&#947;R expressing target cells, which results in increased disease. ADE is well documented to occur after secondary infections with dengue viruses belonging to different serotypes [<xref rid="ppat.1010161.ref039" ref-type="bibr">39</xref>].</p><p>There were initial concerns that SARS-CoV-2 vaccines, in particular whole-inactivated vaccines, might lead to VAERD or ADE. These concerns were heightened by in vitro evidence of ADE for SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV [<xref rid="ppat.1010161.ref040" ref-type="bibr">40</xref>], experimental data indicating eosinophilic VAERD in studies of SARS-CoV and MERS-CoV vaccines in mice [<xref rid="ppat.1010161.ref041" ref-type="bibr">41</xref>,<xref rid="ppat.1010161.ref042" ref-type="bibr">42</xref>], and hepatitis observed in a SARS-CoV ferret model [<xref rid="ppat.1010161.ref043" ref-type="bibr">43</xref>]. These concerns led to the assessment for possible VAERD and ADE by the WHO-COM group in different animal models of SARS-CoV-2 pathogenesis.</p><p>These initial concerns have been now alleviated by several findings in animal models. First, all vaccines that either are emergency use authorized or in late clinical development phases induce strong T-helper 1 (Th1) CD4-mediated responses, which are associated with high ratios of neutralizing versus nonneutralizing antibodies and reduced risk of VAERD [<xref rid="ppat.1010161.ref044" ref-type="bibr">44</xref>]. Moreover, several experiments performed by WHO-COM scientists have utilized experimental alum-adjuvanted and formaldehyde-inactivated whole virus vaccines and subsequent SARS-CoV-2 challenge to address any evidence of VAERD. In rhesus macaques, histopathological analysis revealed no evidence of enhanced lung pathology, and a rapid rise in neutralizing antibodies was seen after challenge [<xref rid="ppat.1010161.ref045" ref-type="bibr">45</xref>]. In hamsters and ferrets, on the other hand, a mild increase of lung pathology was observed at 5 days and 7 days postinoculation (dpi), respectively, in comparison to unvaccinated controls. Nonetheless, in both models, pathology was reduced at 13 dpi to comparable levels for vaccinated and unvaccinated animals. The enhanced pathology was characterized by increased perivascular cuffing (ferrets and hamsters) and greater influx of mononuclear cells and granulocytes in alveoli with thickening of alveolar wall, proliferation of type II pneumocytes, and hemorrhages (hamsters). No clear influx of eosinophils was observed in either species. Noteworthy, hamsters showed no neutralizing antibodies post-immunization and no protection against challenge, but lung cytokines were markedly skewed toward Th2 [<xref rid="ppat.1010161.ref045" ref-type="bibr">45</xref>]. In addition, a recent study in K18-hACE2 mice immunized with a very impure formalin-inactivated SARS-CoV-2 preparation and an aluminum hydroxide-based adjuvant demonstrated earlier onset of SARS-CoV-2 replication and disease in comparison to the na&#239;ve control groups or mRNA-vaccinated animals [<xref rid="ppat.1010161.ref046" ref-type="bibr">46</xref>].</p><p>As VAERD typically develops after vaccine-induced antibody responses wane, it may be too soon to conclude about the presence of VAERD in SARS-CoV-2 vaccination. However, the data currently available from animal experiments, showing the absence of VAERD in NHPs and a transient increase of lung pathology in ferrets and hamsters, are reassuring. Moreover, VAERD has not been reported in humans immunized with inactivated SARS-CoV-2 vaccine preparations.</p></sec><sec id="sec005"><title>Animal models and VOC prophylaxis and therapy</title><p>Despite the rapid and successful development of COVID-19 vaccines, unequal global vaccine distribution has contributed to the rise of VOCs with potential to escape natural as well as vaccine-induced immunity. This, together with the lack of medical countermeasures against severe COVID-19, has resulted in increased efforts to develop prophylactic and therapeutic strategies against SARS-CoV-2 infection, for which animal models are playing a key role. Although revising all therapeutic strategies against COVID-19 is out of the scope of this study, we would like to point out recent preclinical studies with potential to treat infections caused by VOCs. Of these, the use of polyclonal antibodies or antibody cocktails against the SARS-CoV-2 spike receptor binding domain (RBD) provide an advantage by binding to multiple epitopes, thereby reducing the chance of VOC immune escape. Such strategies have shown potent prophylactic and therapeutic activity in mouse models of infection as well as hamsters [<xref rid="ppat.1010161.ref047" ref-type="bibr">47</xref>,<xref rid="ppat.1010161.ref048" ref-type="bibr">48</xref>]. Alternatively, monoclonal antibodies such as COVA1-18 and P5C3 with broad neutralizing activities have also shown prophylactic effect in hamsters, hACE2 mice, and cynomolgus macaques and potent reduction of virus replication postexposure [<xref rid="ppat.1010161.ref049" ref-type="bibr">49</xref>,<xref rid="ppat.1010161.ref050" ref-type="bibr">50</xref>]. P5C3 has also shown neutralization of all known VOCs to date at picomolar concentrations [<xref rid="ppat.1010161.ref050" ref-type="bibr">50</xref>]. Neutralizing single domain antibodies (nanobodies) can be administered intranasally and have also shown to greatly reduce SARS-CoV-2 replication in hamsters [<xref rid="ppat.1010161.ref051" ref-type="bibr">51</xref>,<xref rid="ppat.1010161.ref052" ref-type="bibr">52</xref>]. A complementary strategy against VOC could be the development of antibody cocktails with enhanced Fc-mediated functions, which have been shown to greatly contribute to SARS-CoV-2 humoral immunity [<xref rid="ppat.1010161.ref053" ref-type="bibr">53</xref>]. Consequently, anti-SARS-CoV-2 monoclonal antibodies with optimized Fc domains have shown potent prophylactic and therapeutic activity in several mouse models and hamsters [<xref rid="ppat.1010161.ref054" ref-type="bibr">54</xref>].</p><p>In the early days of the pandemic, animal models were also key for testing nucleoside analog drugs such as remdesivir [<xref rid="ppat.1010161.ref055" ref-type="bibr">55</xref>] and favipiravir [<xref rid="ppat.1010161.ref056" ref-type="bibr">56</xref>]. More recently, molnupiravir (MK-4482) has shown great potential as an orally available drug, which significantly reduced SARS-CoV-2 replication in hamsters [<xref rid="ppat.1010161.ref057" ref-type="bibr">57</xref>] and prevented transmission in ferrets [<xref rid="ppat.1010161.ref058" ref-type="bibr">58</xref>]. Nucleoside analogs such as favipiravir have also shown synergistic activity in combination with other drugs such as 3CL protease inhibitors in huACE2 mice [<xref rid="ppat.1010161.ref059" ref-type="bibr">59</xref>]. Thus, animal models may be needed to test combination drugs against COVID-19. For this, as we will discuss below, the development of more severe models of disease may be needed.</p></sec><sec id="sec006"><title>The search for an animal model of severe SARS-CoV-2 disease</title><p>One of the main gaps still remaining in the development of SARS-CoV-2 infection models is the identification of a preclinical animal model that recapitulates the severe and lethal form of human COVID-19. Such a model would be of great advantage for several aspects of research. First, it would provide a tool to study the transition from mild to severe disease, which would possibly lead to the identification of disease mechanisms and biomarkers. Second, it would expand the presently available animal models to evaluate vaccines and therapeutics, which could result in urgently needed rescue medical countermeasures. Since the first review published by the WHO-COM [<xref rid="ppat.1010161.ref001" ref-type="bibr">1</xref>], the hamster model has emerged as the one that more closely recapitulates moderate disease in humans. Hamsters not only develop respiratory disease after SARS-CoV-2 infection, but also display some other important clinical hallmarks in patients such as anosmia, neurotropism, and vascular inflammation [<xref rid="ppat.1010161.ref060" ref-type="bibr">60</xref>&#8211;<xref rid="ppat.1010161.ref062" ref-type="bibr">62</xref>]. With some exceptions, most laboratories have observed that hamsters tend to lose weight rapidly after experimental infection with SARS-CoV-2 reaching 5% to 20% or more of body weight loss at the peak of infection. However, in some parts of the world, ethical approvals establish euthanasia endpoints at 20% to 25% of weight loss, while in other laboratories, animals are sometimes allowed to lose 30% of body weight. These regulatory differences complicate the definition of severe disease in animal models of infection. Nevertheless, pathological examination of infected hamster lungs shows evidence of severe interstitial pneumonia with high levels of bronchoalveolar damage and inflammation. Unfortunately, the hamster model presents a few unresolved challenges; for example, there is a need to better understand the relationship between the severity of pulmonary pathology and the mild to moderate clinical signs. In order to address this, it seems imperative to develop more tools to study hamster immunology, for example, antibody panels for multiparametric flow cytometry. Moreover, male hamsters show more severe lung lesions than females and less efficient antibody responses [<xref rid="ppat.1010161.ref063" ref-type="bibr">63</xref>,<xref rid="ppat.1010161.ref064" ref-type="bibr">64</xref>]. In the absence of comorbidities or coinfections, an explanation for these findings is likely dependent on sex-associated differences in immune responses. Indeed, male COVID-19 patients have shown higher levels of proinflammatory cytokines and reduced T cell&#8211;mediated immunity in comparison with female patients [<xref rid="ppat.1010161.ref065" ref-type="bibr">65</xref>]. Whether this is the case also in the hamster model again depends on the development of more advanced tools to study hamster immunology.</p><p>Furthermore, the disease development may also be related to age of the used hamsters with older hamsters showing more severe disease progression [<xref rid="ppat.1010161.ref066" ref-type="bibr">66</xref>], although others found no substantial age-related difference [<xref rid="ppat.1010161.ref067" ref-type="bibr">67</xref>,<xref rid="ppat.1010161.ref068" ref-type="bibr">68</xref>]. Despite the gaps of knowledge, hamsters have become the model of choice for preclinical testing of vaccines and therapeutics together with different species of NHPs [<xref rid="ppat.1010161.ref069" ref-type="bibr">69</xref>&#8211;<xref rid="ppat.1010161.ref072" ref-type="bibr">72</xref>].</p><p>In addition to the hamster model, several murine models of severe disease are now available, including infection of common laboratory strains with mouse-adapted SARS-CoV-2 and certain SARS-CoV-2 VOCs and infection of mice expressing huACE2 transgenically or of mice with &#8220;knock-in&#8221; of huACE2 [<xref rid="ppat.1010161.ref073" ref-type="bibr">73</xref>&#8211;<xref rid="ppat.1010161.ref076" ref-type="bibr">76</xref>]. Mice develop pathological signs of pneumonia that range from mild to severe. In some instances, mice also develop anosmia, a common manifestation of the human COVID-19 [<xref rid="ppat.1010161.ref076" ref-type="bibr">76</xref>]. Mice have the advantage of well-characterized genetics and the availability of mice that are completely or conditionally deleted in genes of interest. In addition, the vast existence of reagents to study immune responses in mice also allows a much better characterization of the immunology related to SARS-CoV-2 compared to hamsters or ferrets.</p><p>Finally, as discussed above, several monoclonal antibodies and small molecule antivirals against SARS-CoV2 [<xref rid="ppat.1010161.ref009" ref-type="bibr">9</xref>] are in development, some of which are approved in the United States or may receive market authorization elsewhere in 2021. An important open question is whether escape or resistant virus variants may emerge against either of these therapies. The current SARS-CoV2 animal infection models typically show a limited duration of virus replication and are therefore not well suited to explore whether, in particular with suboptimal doses of either a monoclonal antibody or a small molecule antiviral, drug-resistant variants may emerge. It will therefore be important to develop SARS-CoV2 infection models in which the virus replicates to sufficiently high titers for extended periods of time without causing severe pathology that would require early euthanasia of these animals. To this end, either strains of animals with immunodeficiencies or the experimental induction of immunodeficiencies by pharmacological interventions would be worth exploring.</p></sec><sec id="sec007"><title>Age and comorbidities</title><p>In human COVID-19 disease, there is a strong association of severe disease with age and/or preexisting comorbidities including cardiac disease, diabetes/obesity, hypertension, and chronic respiratory diseases. For COVID-19, age is the best correlate of poor outcome, with those over the age of 85 having a 630-fold increase in death compared to those 18 to 29 years old (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html</ext-link>). Refinement of preclinical models to recapitulate the effect of age and comorbidities in SARS-CoV-2 infection has been an important effort during the last year.</p><sec id="sec008"><title>Age</title><p>Mouse models were one of the first options to explore the effect of age in SARS-CoV-2 infection. There are numerous mouse models of aging that could be applied to COVID-19 studies. The main strategy has been to cross these mouse models with huACE2 transgenic mice or to use mouse-adapted virus. Overall, these studies indicated that the severity of SARS-CoV-2 infection in C57BL/6 and Balb/c mice is age dependent [<xref rid="ppat.1010161.ref073" ref-type="bibr">73</xref>]. Indeed, young mice were resistant to SARS-CoV infection even if they lacked IFN-I expression or the capacity to mount adaptive immune responses [<xref rid="ppat.1010161.ref077" ref-type="bibr">77</xref>], while aged mice infected with SARS-CoV-2 showed greater weight loss, clinical signs, and pathology than their young counterparts despite comparable viral loads [<xref rid="ppat.1010161.ref073" ref-type="bibr">73</xref>]. Mechanistically, the positive correlation between age and severity in SARS-CoV&#8211;infected mice was associated with increased age-dependent inflammation in the lung [<xref rid="ppat.1010161.ref078" ref-type="bibr">78</xref>], which is consistent with findings in humans [<xref rid="ppat.1010161.ref079" ref-type="bibr">79</xref>].</p><p>The effect of age in SARS-CoV-2 infection has been also evaluated in ferrets. These studies showed that 1- to 2-year-old ferrets had prolonged fever compared to young ferrets, which developed little-to-no fever. Three-year-old ferrets had fevers that lasted out past 10 dpi. In addition, older ferrets lost more weight upon infection and regained it more slowly than younger ferrets [<xref rid="ppat.1010161.ref080" ref-type="bibr">80</xref>]. More severe lung pathology also was noted in the older ferrets at 5 dpi. Of note, older ferrets also had higher viral titers in nasal washes and fecal specimens for a longer period and were more likely to transmit the virus to younger ferrets. This is also consistent with findings in older patients, in which immune senescence, loss of type I IFN responses, decline in antigen presentation, and reduced T cell responses have shown to delay viral clearance [<xref rid="ppat.1010161.ref081" ref-type="bibr">81</xref>,<xref rid="ppat.1010161.ref082" ref-type="bibr">82</xref>].</p><p>This correlation between SARS-CoV-2 infection severity and age has been also confirmed in the NHP model. A study comparing rhesus macaques and baboons suggested that viral pneumonia may persist longer in older animals of either species, and a reduction in antibody responses in aged rhesus macaques [<xref rid="ppat.1010161.ref083" ref-type="bibr">83</xref>]. Aged rhesus macaques also have been shown to have increased rectal shedding, slower viral clearance, higher viral loads, more severe lung pathology, higher levels of proinflammatory cytokines, and greater body weight loss [<xref rid="ppat.1010161.ref084" ref-type="bibr">84</xref>]. Increased shedding of viral RNA from the upper respiratory tract was observed in older cynomolgus macaques in one study, but this was not associated with increased disease severity [<xref rid="ppat.1010161.ref084" ref-type="bibr">84</xref>]. A multiomics study comparing subadult and aged rhesus macaques showed that age did not substantially affect acute disease; however, an age-specific divergence of immune responses emerged during the postacute phase of infection (7 to 21 dpi). As in humans, advanced age resulted in a delayed or impaired induction of antiviral cellular immune responses and a delay in the efficient return to immune homeostasis [<xref rid="ppat.1010161.ref085" ref-type="bibr">85</xref>].</p></sec><sec id="sec009"><title>Comorbidities</title><p>Less is known about the effect of comorbidities during SARS-CoV-2 infection in animal models. The reason is that, with the exception of mice, comorbidities are difficult to model in animal experiments. In mice, however, the huACE2 model can be crossed with other specific models of disease such as diabetes, chronic inflammation, or cardiovascular disease (CDs) models. Alternatively, mouse-adapted SARS-CoV-2 or any of the VOCs containing the N501Y spike protein mutation can be directly used to infect mice. Finally, huACE2 can be also expressed to mouse models of disease via adenovirus delivery. The latter approach has been used to study the effects of CDs and diabetes mellitus in SARS-CoV-2 infection and has shown that preexisting CDs resulted in enhanced inflammation and risk of myocardial injury upon infection [<xref rid="ppat.1010161.ref086" ref-type="bibr">86</xref>], which is consistent with observations in humans [<xref rid="ppat.1010161.ref087" ref-type="bibr">87</xref>]. Another strategy is the induction of comorbidities, in particular diabetes and obesity, through changes in rodent diet. Thus, diet-induced obesity in mice resulted in more severe disease upon infection with N501Y-containing SARS-CoV-2 [<xref rid="ppat.1010161.ref025" ref-type="bibr">25</xref>]. Similarly, hamsters fed a western diet for 16 weeks showed greater weight loss and higher viral loads, as well as prolonged viral shedding compared to controls fed a regular rodent diet [<xref rid="ppat.1010161.ref088" ref-type="bibr">88</xref>]. Despite these differences, there were no significant effects of obesity in respiratory function or SARS-CoV-2&#8211;induced pathology between the 2 groups. Other comorbidities associated with severe disease in COVID-19 have not yet been studied in rodents.</p></sec></sec><sec id="sec010"><title>Correlates of protection</title><p>Establishing the immunological correlates of protection remains a key question for vaccine deployment and evaluation. While high levels of neutralizing antibodies in sera likely are associated with protection against disease, the contribution of cellular immunity to protection, including T cells and Fc-dependent effector antibody functions, remains uncertain. In fact, in Phase III SARS-CoV-2 mRNA and Ad26 vaccine clinical trials, protection against clinical infection could be seen even before the appearance of protective antibody titers in sera [<xref rid="ppat.1010161.ref089" ref-type="bibr">89</xref>]. Moreover, correlates of protection against clinical disease and against asymptomatic infection and transmission likely differ. The establishment of robust correlates of protection is necessary to allow immunobridging, which extrapolates vaccine immunogenicity in humans to a protective effect, based on the immunogenicity and protection observed in animal models. Immunobridging will benefit from standardized immunological assays to quantify correlates of protection across animal experiments and clinical studies (<xref rid="ppat.1010161.g002" ref-type="fig">Fig 2</xref>). It has been used for the expansion of mRNA vaccine approval to younger age groups [<xref rid="ppat.1010161.ref090" ref-type="bibr">90</xref>] and will likely expedite the approval of second-generation vaccines without costly and lengthy efficacy studies. It will also help in determining whether and when boosting is needed, and whether vaccine strain updates are needed. One caveat might be that different vaccines might have different correlates of protection, making a universal correlate of protection difficult to achieve. For example, from NHP studies, it has been suggested that T cells can contribute to protection when antibody levels are suboptimal, or start to wane [<xref rid="ppat.1010161.ref091" ref-type="bibr">91</xref>]. This indicates that correlates for long-term protection for an individual may change over time or may include multiple immune parameters. Therefore, it will be important to define immune thresholds for protection. These thresholds can be different for different target groups (the very young, the elderly, pregnant, immune-compromised, or people with comorbidities), which is currently being investigated in the available animal models that reflect the physiological and immunological status of these target groups. Meta-analyses of data generated in clinical trials and postapproval are crucial to validate the correlates of protection identified in preclinical studies.</p><p>Animal models also might be valuable to validate correlates of protection from infection, disease, and transmission. Passive antibody studies in multiple animal models have demonstrated that high titers of polyclonal or monoclonal neutralizing antibodies can protect from disease. Similarly, T cell depletion experiments and adoptive transfer experiments analogously can address the contribution of T cell immunity in protection from disease in mice and NHPs.</p><fig position="float" id="ppat.1010161.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.ppat.1010161.g002</object-id><label>Fig 2</label><caption><title>Animal models and immunobridging.</title><p>Comparative and standardized studies in animal models such as those performed by WHO-COM scientists can help to extrapolate vaccine immunogenicity data across preclinical and clinical studies. Figure created with Biorender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biorender.com/" ext-link-type="uri">Biorender.com</ext-link>). VAERD, vaccine-associated enhanced respiratory disease; VOC, variant of concern; WHO-COM, WHO COVID-19 Modeling group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ppat.1010161.g002.jpg"/></fig></sec><sec id="sec011"><title>Conclusions and future course</title><p>Animal models for SARS-CoV-2 infection have fostered the development of COVID-19 vaccines and therapeutics during the first year of the pandemic, several of which have been deployed on a global scale. Going forward, animal models can still fill important knowledge gaps. For example, preclinical animal studies will be important to understand disease progression and identify biomarkers that can aid us better predict the course of human disease. Animal model studies likely will allow the experimental validation of predicted correlates of protective or dysregulated immunity in humans. Similarly, animal models will be essential to evaluate VOC pathogenicity and transmissibility and to further assess the potential risk of VAERD, especially in the context of heterologous vaccination regimens. It will also be essential to develop SARS-CoV-2 animal infection models in which the virus replicates for extended periods of time, thus allowing for assessment of emergence of resistant variants against vaccines or therapies. Finally, as there is still much to learn about the role of comorbidities in human COVID-19, animal models with comorbidities will be needed to dissect the role of infection versus comorbidity in disease severity. These efforts may also lead to the design and evaluation of specific therapies against severe COVID-19 that function best in the background of particular medical conditions.</p></sec></body><back><ref-list><title>References</title><ref id="ppat.1010161.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Munoz-Fontela</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dowling</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Funnell</surname><given-names>SGP</given-names></name>, <name name-style="western"><surname>Gsell</surname><given-names>P-S</given-names></name>, <name name-style="western"><surname>Riveros-Balta</surname><given-names>AX</given-names></name>, <name name-style="western"><surname>Albrecht</surname><given-names>RA</given-names></name>, <etal>et al</etal>. <article-title>Animal models for COVID-19</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2020</year>;<volume>586</volume>:<fpage>509</fpage>&#8211;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2787-6</pub-id><pub-id pub-id-type="pmid">32967005</pub-id><pub-id pub-id-type="pmcid">PMC8136862</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref002"><label>2</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Zahn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wegmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Loos</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2020</year>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmid">32731257</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Lambe</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Spencer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Purushotham</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Port</surname><given-names>JR</given-names></name>, <etal>et al</etal>. <article-title>ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory Preprints. <year>2020</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2020.05.13.093195</pub-id><pub-id pub-id-type="pmid">32511340</pub-id><pub-id pub-id-type="pmcid">PMC7241103</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Flynn</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Foulds</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Francica</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Werner</surname><given-names>AP</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates</article-title>. <source>N Engl J Med</source>. <year>2020</year>:<fpage>NEJMoa2024671</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa2024671</pub-id><pub-id pub-id-type="pmid">32722908</pub-id><pub-id pub-id-type="pmcid">PMC7449230</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vogel</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Kanevsky</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Che</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Swanson</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Muik</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vormehr</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>BNT162b vaccines protect rhesus macaques from SARS-CoV-2</article-title>. <source>Nature.</source> Nature Publishing Group; <year>2021</year>;<volume>592</volume>:<fpage>283</fpage>&#8211;<lpage>89</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-021-03275-y</pub-id><pub-id pub-id-type="pmid">33524990</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Krause</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Fleming</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Longini</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Peto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Briand</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Heymann</surname><given-names>DL</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 Variants and Vaccines</article-title>. <source>N Engl J Med</source>. Massachusetts Medical Society; <year>2021</year>;<volume>385</volume>:<fpage>179</fpage>&#8211;<lpage>86</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMsr2105280</pub-id><pub-id pub-id-type="pmid">34161052</pub-id><pub-id pub-id-type="pmcid">PMC8262623</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rambaut</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>O&#8217;Toole</surname><given-names>&#193;</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>V</given-names></name>, <name name-style="western"><surname>McCrone</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Ruis</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</article-title>. <source>Nat Microbiol.</source> Nature Publishing Group; <year>2020</year>;<volume>5</volume>:<fpage>1403</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-020-0770-5</pub-id><pub-id pub-id-type="pmid">32669681</pub-id><pub-id pub-id-type="pmcid">PMC7610519</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yinda</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Port</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Bushmaker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fischer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Holbrook</surname><given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.</article-title><source>Emerg Microbes Infect</source>. Taylor &amp; Francis; <year>2021</year>;<volume>10</volume>:<fpage>1284</fpage>&#8211;<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/22221751.2021.1943539</pub-id><pub-id pub-id-type="pmid">34120579</pub-id><pub-id pub-id-type="pmcid">PMC8238069</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abdelnabi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Boudewijns</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Foo</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Seldeslachts</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sanchez-Felipe</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters</article-title>. <source>EBioMedicine</source>. <year>2021</year>;<volume>68</volume>:<fpage>103403</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103403</pub-id><pub-id pub-id-type="pmid">34049240</pub-id><pub-id pub-id-type="pmcid">PMC8143995</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nu&#241;ez</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Lien</surname><given-names>CZ</given-names></name>, <name name-style="western"><surname>Selvaraj</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Stauft</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Starost</surname><given-names>MF</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 B.1.1.7 Infection of Syrian Hamster Does Not Cause More Severe Disease, and Naturally Acquired Immunity Confers Protection</article-title>. <source>mSphere</source>. <year>2021</year>:<fpage>e0050721</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/mSphere.00507-21</pub-id><pub-id pub-id-type="pmid">34133199</pub-id><pub-id pub-id-type="pmcid">PMC8265669</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hassan</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>Shrihari</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gorman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yaun</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Raju</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>An intranasal vaccine durably protects against SARS-CoV-2 variants in mice</article-title>. <source>Cell Rep.</source><year>2021</year>;<volume>36</volume>:<fpage>109452</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109452</pub-id><pub-id pub-id-type="pmid">34289385</pub-id><pub-id pub-id-type="pmcid">PMC8270739</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jacob-Dolan</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques</article-title>. <source>Nature.</source> Nature Publishing Group; <year>2021</year>;<volume>596</volume>:<fpage>423</fpage>&#8211;<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-021-03732-8</pub-id><pub-id pub-id-type="pmid">34161961</pub-id><pub-id pub-id-type="pmcid">PMC8373608</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jacob-Dolan</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Martinot</surname><given-names>AJ</given-names></name>, <etal>et al</etal>. <article-title>Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern</article-title>. <source>Sci Transl Med.</source> American Association for the Advancement of Science; <year>2021</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/scitranslmed.abj3789</pub-id><pub-id pub-id-type="pmid">34705477</pub-id><pub-id pub-id-type="pmcid">PMC8818312</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mohandas</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Shete</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nyayanit</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lole</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters</article-title>. <source>Viruses</source>. Multidisciplinary Digital Publishing Institute; <year>2021</year>;<volume>13</volume>:<fpage>1773</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/v13091773</pub-id><pub-id pub-id-type="pmid">34578354</pub-id><pub-id pub-id-type="pmcid">PMC8473140</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Jacob-Dolan</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants</article-title>. <source>Sci Transl Med</source>. American Association for the Advancement of Science; <year>2021</year>;<volume>13</volume>:<fpage>eabj2641</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/scitranslmed.abj2641</pub-id><pub-id pub-id-type="pmid">34546094</pub-id><pub-id pub-id-type="pmcid">PMC8829873</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brustolin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rodon</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rodr&#237;guez de la Concepci&#243;n</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>&#193;vila-Nieto</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cantero</surname><given-names>G</given-names></name>, <name name-style="western"><surname>P&#233;rez</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster</article-title>. <source>Emerg Microbes Infect</source>. Taylor &amp; Francis; <year>2021</year>;<volume>10</volume>:<fpage>797</fpage>&#8211;<lpage>809</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/22221751.2021.1913974</pub-id><pub-id pub-id-type="pmid">33825619</pub-id><pub-id pub-id-type="pmcid">PMC8812745</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gaudreault</surname><given-names>NN</given-names></name>, <name name-style="western"><surname>Trujillo</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Carossino</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meekins</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Morozov</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Madden</surname><given-names>DW</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 infection, disease and transmission in domestic cats</article-title>. <source>Emerg Microbes Infect</source>. Taylor &amp; Francis; <year>2020</year>;<volume>9</volume>:<fpage>2322</fpage>&#8211;<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/22221751.2020.1833687</pub-id><pub-id pub-id-type="pmid">33028154</pub-id><pub-id pub-id-type="pmcid">PMC7594869</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Eyre</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Purver</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fowler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pouwels</surname><given-names>KB</given-names></name>, <etal>et al</etal>. <article-title>The impact of SARS-CoV-2 vaccination on Alpha &amp; Delta variant transmission</article-title>. <source>medRxiv</source>. Cold Spring Harbor Laboratory Press; <year>2021</year>:2021.09.28.21264260. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.09.28.21264260</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Marsh</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>McAuley</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Au</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Riddell</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Layton</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Singanallur</surname><given-names>NB</given-names></name>, <etal>et al</etal>. <article-title>ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets</article-title>. <source>NPJ Vaccines</source>. Nature Publishing Group; <year>2021</year>;<volume>6</volume>:<fpage>67</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41541-021-00315-6</pub-id><pub-id pub-id-type="pmid">33972565</pub-id><pub-id pub-id-type="pmcid">PMC8110954</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Purushotham</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Holbrook</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Bushmaker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Carmody</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models</article-title>. <source>Sci Transl Med</source>. American Association for the Advancement of Science; <year>2021</year>;<volume>13</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/scitranslmed.abh0755</pub-id><pub-id pub-id-type="pmid">34315826</pub-id><pub-id pub-id-type="pmcid">PMC9267380</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Thao</surname><given-names>TTN</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Taddeo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Labroussaa</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 spike D614G change enhances replication and transmission</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2021</year>;<volume>592</volume>:<fpage>122</fpage>&#8211;<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-021-03361-1</pub-id><pub-id pub-id-type="pmid">33636719</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ulrich</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Halwe</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Taddeo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sch&#246;n</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Devisme</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Enhanced fitness of SARS-CoV-2 variant of concern B.1.1.7, but not B.1.351, in animal models</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.06.28.450190. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.06.28.450190</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Port</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Yinda</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Avanzato</surname><given-names>VA</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Holbrook</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.07.26.453518. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.07.26.453518</pub-id><pub-id pub-id-type="pmid">34341792</pub-id><pub-id pub-id-type="pmcid">PMC8328059</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cool</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gaudreault</surname><given-names>NN</given-names></name>, <name name-style="western"><surname>Morozov</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Trujillo</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Meekins</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>McDowell</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Infection and transmission of SARS-CoV-2 and its alpha variant in pregnant white-tailed deer</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.08.15.456341. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.08.15.456341</pub-id><pub-id pub-id-type="pmid">34842046</pub-id><pub-id pub-id-type="pmcid">PMC8725908</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rathnasinghe</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jangra</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cupic</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mart&#237;nez-Romero</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mulder</surname><given-names>LCF</given-names></name>, <name name-style="western"><surname>Kehrer</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera</article-title>. <source>medRxiv</source>. Cold Spring Harbor Laboratory Press; <year>2021</year>:2021.01.19.21249592. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.01.19.21249592</pub-id><pub-id pub-id-type="pmid">33501468</pub-id><pub-id pub-id-type="pmcid">PMC7836140</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tarr&#233;s-Freixas</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Trinit&#233;</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pons-Gr&#237;fols</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Romero-Durana</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Riveira-Mu&#241;oz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>&#193;vila-Nieto</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.08.03.454861. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.08.03.454861</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Montagutelli</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Prot</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Levillayer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Salazar</surname><given-names>EB</given-names></name>, <name name-style="western"><surname>Jouvion</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Conquet</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.03.18.436013. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.03.18.436013</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Ge</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lan</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species</article-title>. <source>Immunity</source>. <year>2021</year>;<volume>54</volume>:<fpage>1611</fpage>&#8211;<lpage>21.e5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.immuni.2021.06.003</pub-id><pub-id pub-id-type="pmid">34166623</pub-id><pub-id pub-id-type="pmcid">PMC8185182</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pizzorno</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Padey</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dubois</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Julien</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Traversier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Duli&#232;re</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2</article-title>. <source>Antiviral Res</source>. <year>2020</year>;<volume>181</volume>:<fpage>104878</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104878</pub-id><pub-id pub-id-type="pmid">32679055</pub-id><pub-id pub-id-type="pmcid">PMC7361110</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Funnell</surname><given-names>SGP</given-names></name>, <name name-style="western"><surname>Dowling</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Munoz-Fontela</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gsell</surname><given-names>P-S</given-names></name>, <name name-style="western"><surname>Ingber</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>GA</given-names></name>, <etal>et al</etal>. <article-title>Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients</article-title>. <source>Nat Commun</source>. Nature Publishing Group; <year>2020</year>;<volume>11</volume>:<fpage>4253</fpage>&#8211;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-020-17907-w</pub-id><pub-id pub-id-type="pmid">32848158</pub-id><pub-id pub-id-type="pmcid">PMC7450055</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Flagg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>BN</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>P&#233;rez-P&#233;rez</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.05.07.443115. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.05.07.443115</pub-id><pub-id pub-id-type="pmid">34678071</pub-id><pub-id pub-id-type="pmcid">PMC8535829</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rosenke</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Okumura</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Tang-Huau</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Meade-White</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>UK B.1.1.7 variant exhibits increased respiratory replication and shedding in nonhuman primates</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.06.11.448134. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.06.11.448134</pub-id><pub-id pub-id-type="pmid">34724885</pub-id><pub-id pub-id-type="pmcid">PMC8635622</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Thorne</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Bouhaddou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Reuschl</surname><given-names>A-K</given-names></name>, <name name-style="western"><surname>Zuliani-Alvarez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ben Polacco</surname></name>, <name name-style="western"><surname>Pelin</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.06.06.446826. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.06.06.446826</pub-id><pub-id pub-id-type="pmid">34127972</pub-id><pub-id pub-id-type="pmcid">PMC8202424</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Escalera</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gonzalez-Reiche</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Aslam</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mena</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pearl</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Laporte</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.08.05.455290. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.08.05.455290</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref035"><label>35</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peacock</surname><given-names>TP</given-names></name>, <name name-style="western"><surname>Sheppard</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Goonawardane</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Whiteley</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.05.28.446163. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.05.28.446163</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref036"><label>36</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Thi Nhu Thao</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Labroussaa</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>N</given-names></name>, <name name-style="western"><surname>V&#8217;kovski</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Stalder</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Portmann</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2020</year>;<volume>582</volume>:<fpage>561</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2294-9</pub-id><pub-id pub-id-type="pmid">32365353</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref037"><label>37</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Canchola</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Brandt</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Pyles</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Chanock</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title>. <source>Am J Epidemiol</source>. <year>1969</year>;<volume>89</volume>:<fpage>422</fpage>&#8211;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120955</pub-id><pub-id pub-id-type="pmid">4305198</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref038"><label>38</label><mixed-citation publication-type="journal"><name name-style="western"><surname>R&#248;d</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Haug</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Ulstrup</surname><given-names>JC</given-names></name>. <article-title>Atypical measles after vaccination with killed vaccine</article-title>. <source>Scand J Infect Dis</source>. Taylor &amp; Francis; <year>1970</year>;<volume>2</volume>:<fpage>161</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3109/inf.1970.2.issue-3.02</pub-id><pub-id pub-id-type="pmid">25607573</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref039"><label>39</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Roy</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Bhattacharjee</surname><given-names>S</given-names></name>. <article-title>Dengue virus: epidemiology, biology, and disease aetiology</article-title>. <source>Can J Microbiol</source>. NRC Research Press 1840 Woodward Drive, Suite 1, Ottawa, ON K2C 0P7; <year>2021</year>:<fpage>1</fpage>&#8211;<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1139/cjm-2020-0572</pub-id><pub-id pub-id-type="pmid">34171205</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref040"><label>40</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tai</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Geng</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry</article-title>. <source>J Virol</source>. <year>2020</year>:<volume>94</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.02015-19</pub-id><pub-id pub-id-type="pmid">31826992</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref041"><label>41</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bolles</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Deming</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Whitmore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ferris</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title>. <source>J Virol</source>. <year>2011</year>;<volume>85</volume>:<fpage>12201</fpage>&#8211;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.06048-11</pub-id><pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref042"><label>42</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tseng</surname><given-names>C-T</given-names></name>, <name name-style="western"><surname>Sbrana</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Newman</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Garron</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Atmar</surname><given-names>RL</given-names></name>, <etal>et al</etal>. <article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. Poehlmann S, editor</article-title>. <source>PLoS ONE</source>. Public Library of Science; <year>2012</year>;<volume>7</volume>:<fpage>e35421</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmid">22536382</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref043"><label>43</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Weingartl</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Czub</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Czub</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Neufeld</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Marszal</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gren</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title>. <source>J Virol</source>. <year>2004</year>;<volume>78</volume>:<fpage>12672</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/JVI.78.22.12672-12676.2004</pub-id><pub-id pub-id-type="pmid">15507655</pub-id><pub-id pub-id-type="pmcid">PMC525089</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref044"><label>44</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Munoz</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Cramer</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Dekker</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Dudley</surname><given-names>MZ</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Gurwith</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data</article-title>. <source>Vaccine</source>. <year>2021</year>;<volume>39</volume>:<fpage>3053</fpage>&#8211;<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.01.055</pub-id><pub-id pub-id-type="pmid">33637387</pub-id><pub-id pub-id-type="pmcid">PMC7901381</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref045"><label>45</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bewley</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Gooch</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Longet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wiblin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques</article-title>. <source>Sci Adv</source>. American Association for the Advancement of Science; <year>2021</year>;<volume>7</volume>:<fpage>eabg7996</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/sciadv.abg7996</pub-id><pub-id pub-id-type="pmid">34516768</pub-id><pub-id pub-id-type="pmcid">PMC8442907</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref046"><label>46</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hoffmann</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Corleis</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Rauch</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>N</given-names></name>, <name name-style="western"><surname>M&#252;he</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Halwe</surname><given-names>NJ</given-names></name>, <etal>et al</etal>. <article-title>CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2</article-title>. <source>Nat Commun</source>. Nat Publ Group. <year>2021</year>;<volume>12</volume>:<fpage>4048</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-24339-7</pub-id><pub-id pub-id-type="pmid">34193869</pub-id><pub-id pub-id-type="pmcid">PMC8245475</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref047"><label>47</label><mixed-citation publication-type="journal"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System</article-title>. <source>Front Immunol Frontiers</source>. <year>2021</year>;<volume>12</volume>:<fpage>689065</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2021.689065</pub-id><pub-id pub-id-type="pmid">34733269</pub-id><pub-id pub-id-type="pmcid">PMC8559598</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref048"><label>48</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Su</surname><given-names>S-C</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>T-J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>P-Y</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>K-H</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>W-Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>C-W</given-names></name>, <etal>et al</etal>. <article-title>Structure-guided antibody cocktail for prevention and treatment of COVID-19</article-title>. <source>PLoS Pathog</source>. <year>2021</year>;<volume>17</volume>:<fpage>e1009704</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1009704</pub-id><pub-id pub-id-type="pmid">34673836</pub-id><pub-id pub-id-type="pmcid">PMC8530329</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref049"><label>49</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maisonnasse</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Aldon</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Marc</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Marlin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dereuddre-Bosquet</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kuzmina</surname><given-names>NA</given-names></name>, <etal>et al</etal>. <article-title>COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models</article-title>. <source>Nat Commun</source>. Nature Publishing Group. <year>2021</year>;<volume>12</volume>:<fpage>6097</fpage>&#8211;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-26354-0</pub-id><pub-id pub-id-type="pmid">34671037</pub-id><pub-id pub-id-type="pmcid">PMC8528857</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref050"><label>50</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fenwick</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Turelli</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Perez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pellaton</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Esteves-Leuenberger</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Farina</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>A highly potent antibody effective against SARS-CoV-2 variants of concern</article-title>. <source>Cell Rep</source>. <year>2021</year>;<volume>37</volume>:<fpage>109814</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109814</pub-id><pub-id pub-id-type="pmid">34599871</pub-id><pub-id pub-id-type="pmcid">PMC8452523</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref051"><label>51</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Haga</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Takai-Todaka</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Matsumura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Takano</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tojo</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model</article-title>. <source>PLoS Pathog</source>. Public Library of Science; <year>2021</year>;<volume>17</volume>:<fpage>e1009542</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1009542</pub-id><pub-id pub-id-type="pmid">34648602</pub-id><pub-id pub-id-type="pmcid">PMC8516304</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref052"><label>52</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mikolajek</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Le Bas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kipar</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19</article-title>. <source>Nat Commun.</source> Nature Publishing Group; <year>2021</year>;<volume>12</volume>:<fpage>5469</fpage>&#8211;<lpage>18</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-25480-z</pub-id><pub-id pub-id-type="pmid">34552091</pub-id><pub-id pub-id-type="pmcid">PMC8458290</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref053"><label>53</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kaplonek</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bartsch</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fischinger</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gorman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Bowman</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Early cross-coronavirus reactive signatures of humoral immunity against COVID-19</article-title>. <source>Sci Immunol</source>. <year>2021</year>;<volume>6</volume>:<fpage>eabj2901</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/sciimmunol.abj2901</pub-id><pub-id pub-id-type="pmid">34652962</pub-id><pub-id pub-id-type="pmcid">PMC8943686</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref054"><label>54</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yamin</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>H-H</given-names></name>, <name name-style="western"><surname>Sch&#228;fer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kao</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Francis</surname><given-names>RL</given-names></name>, <etal>et al</etal>. <article-title>Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2021</year>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-021-04017-w</pub-id><pub-id pub-id-type="pmid">34547765</pub-id><pub-id pub-id-type="pmcid">PMC9038156</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref055"><label>55</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Williamson</surname><given-names>BN</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Meade-White</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Porter</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2020</year>:<fpage>1</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2423-5</pub-id><pub-id pub-id-type="pmid">32516797</pub-id><pub-id pub-id-type="pmcid">PMC7486271</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref056"><label>56</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kaptein</surname><given-names>SJF</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Langendries</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Seldeslachts</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Horst ter</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Liesenborghs</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity</article-title>. <source>Proc Natl Acad Sci U S A</source>. National Academy of Sciences; <year>2020</year>;<volume>117</volume>:<fpage>26955</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2014441117</pub-id><pub-id pub-id-type="pmid">33037151</pub-id><pub-id pub-id-type="pmcid">PMC7604414</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref057"><label>57</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rosenke</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Haddock</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rosenke</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model</article-title>. <source>Nat Commun</source>. Nature Publishing Group; <year>2021</year>;<volume>12</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-020-20314-w</pub-id><pub-id pub-id-type="pmid">33863887</pub-id><pub-id pub-id-type="pmcid">PMC8052374</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref058"><label>58</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cox</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Plemper</surname><given-names>RK</given-names></name>. <article-title>Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets</article-title>. <source>Nat Microbiol</source>. Nature Publishing Group; <year>2021</year>;<volume>6</volume>:<fpage>11</fpage>&#8211;<lpage>18</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-020-00835-2</pub-id><pub-id pub-id-type="pmid">33273742</pub-id><pub-id pub-id-type="pmcid">PMC7755744</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref059"><label>59</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Boras</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Anson</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Arenson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Aschenbrenner</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bakowski</surname><given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19</article-title>. <source>Nat Commun.</source> Nature Publishing Group; <year>2021</year>;<volume>12</volume>:<fpage>6055</fpage>&#8211;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-26239-2</pub-id><pub-id pub-id-type="pmid">34663813</pub-id><pub-id pub-id-type="pmcid">PMC8523698</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref060"><label>60</label><mixed-citation publication-type="journal"><name name-style="western"><surname>de Melo</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Lazarini</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Levallois</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hautefort</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Michel</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Larrous</surname><given-names>F</given-names></name>, <etal>et al</etal>. <article-title>COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters</article-title>. <source>Sci Transl Med</source>. American Association for the Advancement of Science; <year>2021</year>;<volume>13</volume>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/scitranslmed.abf8396</pub-id><pub-id pub-id-type="pmid">33941622</pub-id><pub-id pub-id-type="pmcid">PMC8158965</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref061"><label>61</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Allnoch</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Beythien</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Leitzen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kaup</surname><given-names>F-J</given-names></name>, <name name-style="western"><surname>Stanelle-Bertram</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Vascular Inflammation Is Associated with Loss of Aquaporin 1 Expression on Endothelial Cells and Increased Fluid Leakage in SARS-CoV-2 Infected Golden Syrian Hamsters.</article-title><source>Viruses</source>. Multidisciplinary Digital Publishing Institute; <year>2021</year>;<volume>13</volume>:<fpage>639</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/v13040639</pub-id><pub-id pub-id-type="pmid">33918079</pub-id><pub-id pub-id-type="pmcid">PMC8069375</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref062"><label>62</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Becker</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Beythien</surname><given-names>G</given-names></name>, <name name-style="western"><surname>de Buhr</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Stanelle-Bertram</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tuku</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kouassi</surname><given-names>NM</given-names></name>, <etal>et al</etal>. <article-title>Vasculitis and Neutrophil Extracellular Traps in Lungs of Golden Syrian Hamsters With SARS-CoV-2</article-title>. <source>Front Immunol</source>. Frontiers. <year>2021</year>;<volume>12</volume>:<fpage>640842</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2021.640842</pub-id><pub-id pub-id-type="pmid">33912167</pub-id><pub-id pub-id-type="pmcid">PMC8072219</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref063"><label>63</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dhakal</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ruiz-Bedoya</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Creisher</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Villano</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Littlefield</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model</article-title>. <source>mBio</source>. <year>2021</year>;<volume>12</volume>:<fpage>e0097421</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/mBio.00974-21</pub-id><pub-id pub-id-type="pmid">34253053</pub-id><pub-id pub-id-type="pmcid">PMC8406232</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref064"><label>64</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster</article-title>. <source>Signal Transduct Target Ther</source>. Nature Publishing Group; <year>2021</year>;<volume>6</volume>:<fpage>136</fpage>&#8211;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41392-021-00552-0</pub-id><pub-id pub-id-type="pmid">33790236</pub-id><pub-id pub-id-type="pmcid">PMC8009924</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref065"><label>65</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ellingson</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Israelow</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lucas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Sex differences in immune responses that underlie COVID-19 disease outcomes</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2020</year>;<volume>588</volume>:<fpage>315</fpage>&#8211;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2700-3</pub-id><pub-id pub-id-type="pmid">32846427</pub-id><pub-id pub-id-type="pmcid">PMC7725931</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref066"><label>66</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Osterrieder</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bertzbach</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Dietert</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Abdelgawad</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vladimirova</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kunec</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters</article-title>. <source>Viruses.</source> Multidisciplinary Digital Publishing Institute; <year>2020</year>;<volume>12</volume>:<fpage>779</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/v12070779</pub-id><pub-id pub-id-type="pmid">32698441</pub-id><pub-id pub-id-type="pmcid">PMC7412213</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref067"><label>67</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gerhards</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Cornelissen</surname><given-names>JBWJ</given-names></name>, <name name-style="western"><surname>van Keulen</surname><given-names>LJM</given-names></name>, <name name-style="western"><surname>Harders-Westerveen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vloet</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Smid</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Predictive Value of Precision-Cut Lung Slices for the Susceptibility of Three Animal Species for SARS-CoV-2 and Validation in a Refined Hamster Model</article-title>. <source>Pathogens</source>. Multidisciplinary Digital Publishing Institute; <year>2021</year>;<volume>10</volume>:<fpage>824</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/pathogens10070824</pub-id><pub-id pub-id-type="pmid">34209230</pub-id><pub-id pub-id-type="pmcid">PMC8308566</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref068"><label>68</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Imai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Iwatsuki-Horimoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hatta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Loeber</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Halfmann</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Nakajima</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development</article-title>. <source>Proc Natl Acad Sci U S A</source>. National Academy of Sciences; <year>2020</year>;<volume>117</volume>:<fpage>16587</fpage>&#8211;<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.2009799117</pub-id><pub-id pub-id-type="pmid">32571934</pub-id><pub-id pub-id-type="pmcid">PMC7368255</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref069"><label>69</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Salguero</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>White</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Slack</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Fotheringham</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Bewley</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Gooch</surname><given-names>KE</given-names></name>, <etal>et al</etal>. <article-title>Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19</article-title>. <source>Nat Commun</source>. Nature Publishing Group; <year>2021</year>;<volume>12</volume>:<fpage>1260</fpage>&#8211;<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-21389-9</pub-id><pub-id pub-id-type="pmid">33627662</pub-id><pub-id pub-id-type="pmcid">PMC7904795</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref070"><label>70</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ishigaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kitagawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Shiohara</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques</article-title>. <source>Virology</source>. <year>2021</year>;<volume>554</volume>:<fpage>97</fpage>&#8211;<lpage>105</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.virol.2020.12.013</pub-id><pub-id pub-id-type="pmid">33412411</pub-id><pub-id pub-id-type="pmcid">PMC7771262</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref071"><label>71</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rockx</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kuiken</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Herfst</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bestebroer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lamers</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Oude Munnink</surname><given-names>BB</given-names></name>, <etal>et al</etal>. <article-title>Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model</article-title>. <source>Science</source>. American Association for the Advancement of Science; <year>2020</year>;<volume>368</volume>:<fpage>1012</fpage>&#8211;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.abb7314</pub-id><pub-id pub-id-type="pmid">32303590</pub-id><pub-id pub-id-type="pmcid">PMC7164679</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref072"><label>72</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Feldmann</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>BN</given-names></name>, <name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>P&#233;rez-P&#233;rez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Respiratory disease in rhesus macaques inoculated with SARS-CoV-2</article-title>. <source>Nature</source>. <year>2020</year>;<volume>579</volume>:<fpage>265</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32396922</pub-id><pub-id pub-id-type="pmcid">PMC7486227</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref073"><label>73</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Leist</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Dinnon</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Sch&#228;fer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tse</surname><given-names>LV</given-names></name>, <name name-style="western"><surname>Okuda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>YJ</given-names></name>, <etal>et al</etal>. <article-title>A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice</article-title>. <source>Cell</source>. <year>2020</year>;<volume>183</volume>:<fpage>1070</fpage>&#8211;<lpage>85.e12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.050</pub-id><pub-id pub-id-type="pmid">33031744</pub-id><pub-id pub-id-type="pmcid">PMC7510428</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref074"><label>74</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice.</article-title><source>EBioMedicine</source>. <year>2021</year>;<volume>67</volume>:<fpage>103381</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103381</pub-id><pub-id pub-id-type="pmid">33993052</pub-id><pub-id pub-id-type="pmcid">PMC8118724</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref075"><label>75</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Winkler</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Bailey</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Kafai</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>S</given-names></name>, <name name-style="western"><surname>McCune</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function</article-title>. <source>Nat Immunol</source>. Nature Publishing Group; <year>2020</year>;<volume>21</volume>:<fpage>1327</fpage>&#8211;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41590-020-0778-2</pub-id><pub-id pub-id-type="pmid">32839612</pub-id><pub-id pub-id-type="pmcid">PMC7578095</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref076"><label>76</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>L-YR</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Ortiz</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice</article-title>. <source>Nature</source>. Nature Publishing Group; <year>2021</year>;<volume>589</volume>:<fpage>603</fpage>&#8211;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2943-z</pub-id><pub-id pub-id-type="pmid">33166988</pub-id><pub-id pub-id-type="pmcid">PMC7855185</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref077"><label>77</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Frieman</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Morrison</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Whitmore</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Funkhouser</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism</article-title>. <source>PLoS Pathog</source>. Public Library of Science; <year>2010</year>;<volume>6</volume>:<fpage>e1000849</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.ppat.1000849</pub-id><pub-id pub-id-type="pmid">20386712</pub-id><pub-id pub-id-type="pmcid">PMC2851658</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref078"><label>78</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vijay</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Miki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Gelb</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection</article-title>. <source>J Exp Med</source>. <year>2015</year>;<volume>212</volume>:<fpage>1851</fpage>&#8211;<lpage>68</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1084/jem.20150632</pub-id><pub-id pub-id-type="pmid">26392224</pub-id><pub-id pub-id-type="pmcid">PMC4612096</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref079"><label>79</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bajaj</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Gadi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Spihlman</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Moulton</surname><given-names>VR</given-names></name>. <article-title>Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front Physiol</article-title>. <source>Frontiers</source>. <year>2020</year>;<volume>11</volume>:<fpage>571416</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fphys.2020.571416</pub-id><pub-id pub-id-type="pmid">33510644</pub-id><pub-id pub-id-type="pmcid">PMC7835928</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref080"><label>80</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kim</surname><given-names>Y-I</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>K-M</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>J-Y</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>E-H</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S-M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>EJ</given-names></name>, <etal>et al</etal>. <article-title>Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets</article-title>. <source>Res Sq</source>. <year>2021</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.21203/rs.3.rs-131380/v2</pub-id><pub-id pub-id-type="pmid">35013229</pub-id><pub-id pub-id-type="pmcid">PMC8748994</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref081"><label>81</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Rovina</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Akinosoglou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Antoniadou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Antonakos</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure</article-title>. <source>Cell Host Microbe</source>. <year>2020</year>;<volume>27</volume>:<fpage>992</fpage>&#8211;<lpage>1000</lpage>.e3. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.009</pub-id><pub-id pub-id-type="pmid">32320677</pub-id><pub-id pub-id-type="pmcid">PMC7172841</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref082"><label>82</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rydyznski Moderbacher</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></name>, <name name-style="western"><surname>Dan</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hastie</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Weiskopf</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity</article-title>. <source>Cell</source>. <year>2020</year>;<volume>183</volume>:<fpage>996</fpage>&#8211;<lpage>1012.e19</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id><pub-id pub-id-type="pmid">33010815</pub-id><pub-id pub-id-type="pmcid">PMC7494270</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref083"><label>83</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ganatra</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Gazi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cole</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Thippeshappa</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets</article-title>. <source>Nat Microbiol</source>. Nature Publishing Group; <year>2021</year>;<volume>6</volume>:<fpage>73</fpage>&#8211;<lpage>86</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41564-020-00841-4</pub-id><pub-id pub-id-type="pmid">33340034</pub-id><pub-id pub-id-type="pmcid">PMC7890948</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref084"><label>84</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Blair</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Vaccari</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Doyle-Meyers</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fahlberg</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Acute Respiratory Distress in Aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques</article-title>. <source>Am J Pathol</source>. <year>2021</year>;<volume>191</volume>:<fpage>274</fpage>&#8211;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ajpath.2020.10.016</pub-id><pub-id pub-id-type="pmid">33171111</pub-id><pub-id pub-id-type="pmcid">PMC7648506</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref085"><label>85</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Speranza</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Purushotham</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Port</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Flagg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Williamson</surname><given-names>BN</given-names></name>, <etal>et al</etal>. <article-title>Age-related differences in immune dynamics during SARS-CoV-2 infection in rhesus macaques</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.09.08.459430. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.09.08.459430</pub-id><pub-id pub-id-type="pmcid">PMC8807873</pub-id><pub-id pub-id-type="pmid">35039442</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref086"><label>86</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Qu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>SARS-CoV-2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice</article-title>. <source>Animal Model Exp Med</source>. John Wiley &amp; Sons, Ltd; <year>2021</year>;<volume>4</volume>:<fpage>2</fpage>&#8211;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ame2.12155</pub-id><pub-id pub-id-type="pmid">33738432</pub-id><pub-id pub-id-type="pmcid">PMC7954823</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref087"><label>87</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nishiga</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>JC</given-names></name>. <article-title>COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives</article-title>. <source>Nat Rev Cardiol</source>. Nature Publishing Group; <year>2020</year>;<volume>17</volume>:<fpage>543</fpage>&#8211;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41569-020-0413-9</pub-id><pub-id pub-id-type="pmid">32690910</pub-id><pub-id pub-id-type="pmcid">PMC7370876</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref088"><label>88</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Port</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Adney</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Sturdevant</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>BJ</given-names></name>, <etal>et al</etal>. <article-title>Western diet increases COVID-19 disease severity in the Syrian hamster</article-title>. <source>bioRxiv</source>. Cold Spring Harbor Laboratory; <year>2021</year>:2021.06.17.448814. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.06.17.448814</pub-id><pub-id pub-id-type="pmid">34159329</pub-id><pub-id pub-id-type="pmcid">PMC8219093</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref089"><label>89</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kyriakidis</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gonz&#225;lez</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Grimaldos</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Prado</surname><given-names>EO</given-names></name>. <article-title>SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates</article-title>. <source>NPJ Vaccines</source>. Nature Publishing Group; <year>2021</year>;<volume>6</volume>:<fpage>28</fpage>&#8211;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41541-021-00292-w</pub-id><pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref090"><label>90</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mahase</surname><given-names>E.</given-names></name><article-title>Covid vaccine could be rolled out to children by autumn</article-title>. <source>BMJ</source>. British Medical Journal Publishing Group; <year>2021</year>;<volume>372</volume>:<fpage>n723</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.n723</pub-id><pub-id pub-id-type="pmid">33727232</pub-id></mixed-citation></ref><ref id="ppat.1010161.ref091"><label>91</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McMahan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mercado</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Loos</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tostanoski</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Chandrashekar</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>. <source>Nature.</source> Nature Publishing Group; <year>2021</year>;<volume>590</volume>:<fpage>630</fpage>&#8211;<lpage>34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-03041-6</pub-id><pub-id pub-id-type="pmid">33276369</pub-id><pub-id pub-id-type="pmcid">PMC7906955</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>